期刊文献+

在吸水链霉菌中表达透明颤菌血红蛋白基因提高子囊霉素产量 被引量:2

Enhancement of Ascomycin Production by Expression of Vitreoscilla Hemoglobin Gene in Streptomyces hygroscopicus
原文传递
导出
摘要 为了解决子囊霉素(1)发酵过程低溶氧的问题,本研究将透明颤菌(Vitreoscilla)血红蛋白基因(vgb)整合至1生产菌株吸水链霉菌(Streptomyces hygroscopicus)中,构建工程菌SIPI-FK520-2,通过RT-PCR分析检测到了vgb基因的转录表达,进一步利用CO结合差光谱分析也证实了工程菌中透明颤菌血红蛋白(VHb)具有生物活性。最后在发酵罐进行该工程菌的发酵培养研究,结果表明,与野生菌相比,工程菌发酵过程溶氧水平明显改善,1产量提高了38%,达到1 269.7 mg/L。 In order to solve the shortage of dissolved oxygen in the fermentation process of ascomycin (1),the Vitreoscilla hemoglobin gene (vgb) which encodes Vitreoscilla hemoglobin (VHb) was integrated into 1 producing strain Streptomyces hygroscopicus. The codon-optimized vgb gene was ligased with plasmid pSET-M, making it under the control of constitutive erythromycin resistance gene promoter (ermE*), to yield an recombinant plasmid pSET-vgb.Then, vgb gene was introduced into the genome of S. hygroscopicus SIPI-FK520-1 through conjugal transfer to construct an engineering strain named SIPI-FK520-2. The RT-PCR analysis showed that vgb gene had been successfully expressed in the recombinant engineering strain. The biological activity of VHb in the recombinant strain was further detected and confirmed by CO-binding difference spectroscopy. Finally, the strain was cultured in a 5 L bioreactor. The results indicated that the level of dissolved oxygen in fermentation process was significantly improved, and the yield of 1 was increased by 38% compared to the wild strain, up to 1 269.7 mg/L.
作者 余志拓 沈晓放 吴远杰 杨松柏 陈少欣 YU Zhituo SHEN Xiaofang WU Yuanjie YANG Songbai CHEN Shaoxin(State Key Lab. of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 201203)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2017年第6期844-849,共6页 Chinese Journal of Pharmaceuticals
基金 国家"重大新药创制"科技重大专项(2014ZX09201001-005-001)
关键词 子囊霉素 透明颤菌血红蛋白 吸水链霉菌 基因工程 溶氧 大环内酯抗生素 抗菌药 免疫抑制药 ascomycin Vitreoscilla hemoglobin Streptomyces hygroscopicus genetic engineering dissolved oxygen macrolide-antibiotic antibacterial immunosuppressant
  • 相关文献

参考文献2

二级参考文献33

  • 1Masakuni Okuhazu, HannLa, Toshi Goto, et al. Tricyclo compounds, a process for their production and pharmaceutical composition containing the same: US, 4894366 [P]. 1990-01-16.
  • 2Arai T, Kouama Y, Suenage T, et al. Ascomycin, an antifungal antibiotic [J]. J. Antibiotics, 1962, 15: 231-232.
  • 3Wang-Fana Weizheng, Kustersa E, Lohsea O, et al. Application of centrifugal counter-current chromatography to the separation of macrolide antibiotic analogues I . Selection of solvent systems based on solubility and partition coefficient investigations [J]. Journal of Chromatography A, 1999, 864: 69-76.
  • 4Schnopp C, Remling R, Mohrenschlager M, et al. Topical taerolimus (FK506) and mometasone furoate in treatment of dyshidrotie palmar eczema: a randomized, observer blinded trial [J]. J. Am. Acad. Dermatol., 2002, 46 (1): 73-76.
  • 5Ruzicka T, Assmann T, Homey B Tacrolimus. The drug for the turn of the millennium [J]. J. Am. Arch. Dermatol., 1999, 135 (5): 574-580.
  • 6Schreiber S L, Crabtree G R. The mechanism of action of cyclosporing A and FK506 [J].Immunol Today, 1992, 13 (4): 136-142.
  • 7Panhans-Gross A, Novak N, Kraft S, et al. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506) [J]. J. Allergy Clin Immunol, 2001, 107 (2):345-352.
  • 8Stuetz A, Grassberger M, Meingassner J G.Pimecrolimus (Elidel, SDZ, ASM981 )preclinical pharmacologic profile and skin selectivity [J].Semi. Cutan Med. Surg., 2001, 20 (4): 233-241.
  • 9Boguniewicz M, Leung D Y. Pathophysiologic mechanisms in atopic dermatitics[J]. Semin Cutan Med. Surg., 2001, 20 (4): 217-225.
  • 10清华大学国际技术转移中心.子囊霉素菌种及工艺概要[EB/OL] [2008-07-07]. http://www.ittc.com.cn/view.asp?cat0_id=2&cat1_id=12&id=2610.

共引文献17

同被引文献19

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部